Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer
Open accessThe DOI matches its Crossref record; 89 of the 89 references it cites were found in a registry or an index; 17 of the 98 sources its claims cite were checked for support.
Abstract
Metastatic colorectal cancer remains a deadly malignancy and is the third leading cause of cancer-related death. The mainstay of treatment for metastatic colorectal cancer is chemotherapy, but unfortunately, even with recent progress, overall survival is still poor. Colorectal cancer is a heterogeneous disease, and the underlying genetic differences among tumors can define the behavior and prognosis of the disease. Given the limitations of cytotoxic chemotherapy, research has focused on developing targeted therapy based on molecular subtyping. Since the early 2000s, multiple targeted therapies have demonstrated efficacy in treating metastatic colorectal cancer and have received FDA approval. The epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF), and DNA mismatch repair pathways have demonstrated promising results for targeted therapies. As new gene mutations and proteins involved in the oncogenesis of metastatic colorectal cancer are identified, new targets will continue to emerge. We herein provide a summary of the updated literature regarding targeted therapies for patients with mCRC.
Overview
CoChat Summary
TL;DR
This narrative review summarizes targeted therapy and immunotherapy options for metastatic colorectal cancer by molecular pathway, including EGFR, VEGF, HER2, immune checkpoint, and NTRK targets. It emphasizes molecular profiling, tumor sidedness, MSI status, and HER2/NTRK alterations as determinants of therapy selection, while noting resistance mechanisms and the need for better biomarkers.
Key findings
- EGFR-directed therapy benefits are limited mainly to left-sided KRAS wild-type tumors; in TAILOR, FOLFOX plus cetuximab improved overall survival versus FOLFOX alone (20.7 vs. 17.8 months), while the EPOC trial found median overall survival of 81.0 months with chemotherapy versus 55.4 months with cetuximab plus chemotherapy in operable liver metastases, leading the authors to advise against cetuximab in that setting.
- VEGF-pathway agents show survival gains in metastatic colorectal cancer: bevacizumab plus IFL improved median overall survival versus IFL alone (20.3 vs. 15.6 months); aflibercept plus FOLFIRI improved overall survival versus FOLFIRI (13.5 vs. 12.1 months); ramucirumab plus FOLFIRI improved overall survival versus placebo plus FOLFIRI (13.3 vs. 11.7 months); regorafenib improved median overall survival versus placebo (6.4 vs. 5.0 months); and fruquintinib improved overall survival versus placebo in FRESCO (9.3 vs. 6.6 months) and FRESCO-2 (7.4 vs. 4.8 months, p < 0.001).
- HER2 amplification occurs in approximately 3–5% of colorectal cancers; in MOUNTAINEER, tucatinib plus trastuzumab produced an objective response rate of 38.1%, and in DESTINY-CRC01, trastuzumab deruxtecan produced an objective response rate of 45.3%, median overall survival of 15.5 months, and progression-free survival of 6.9 months.
- In MSI-high tumors, pembrolizumab improved progression-free survival versus chemotherapy in KEYNOTE-177 (median 16.5 vs. 8.2 months, HR 0.60, p < 0.001), and first-line nivolumab plus ipilimumab in CheckMate 142 produced an objective response rate of 69%, disease control rate of 84%, and 13% complete response rate; atezolizumab added to FOLFOXIRI plus bevacizumab in AtezoTRIBE improved progression-free survival versus control (13.1 vs. 11.5 months, HR 0.69, p = 0.012).
Methods
- Broad literature review using MEDLINE/PubMed, with search ending 15 December 2023; search terms included “targeted therapy,” “colon cancer,” “colorectal cancer,” and “immunotherapy.”
- Inclusion prioritized clinical trials related to targeted therapy and immunotherapy for colorectal cancer metastasis; two authors performed initial review, and the senior author made final inclusion determinations.
- The paper is a narrative review, not a systematic review or meta-analysis.
Limitations
- Stated limitations: Not stated in the paper.
- Evident from the text: the review is broad and narrative rather than systematic, with no formal risk-of-bias assessment or quantitative synthesis, and the search ended in December 2023.
- Evident from the text: many included trials differ in setting, line of therapy, endpoints, and maturity; for example, overall survival data for sotorasib plus panitumumab were not yet available, and several phase 3 trials were ongoing, limiting direct cross-trial comparisons.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 The EGFR pathway demonstrates multiple targets, including the EGFR, RAS, BRAF V600E, and MEK. The figure was adapted from [13].](https://figures.cochat.ai/paper-figures/b0ade5266a6f49e994dd1e534ad50b9e/update-on-targeted-therapy-and-immunotherapy-for-metastatic-colorectal-cancer-figure-1.jpg)
![Figure 2 The VEGF pathway illustrates the mechanism through which the VEGF receptor elicits angiogenesis. The figure was adapted from [44].](https://figures.cochat.ai/paper-figures/bb5bbcee445247f5ac8ad7de596f52ef/update-on-targeted-therapy-and-immunotherapy-for-metastatic-colorectal-cancer-figure-2.jpg)
Verification
Claims the paper makes
13 Valid · 1 Not valid · 80 Not checked · 15 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“the median overall survival was 81.0 months in the chemotherapy group and 55.4 months in the cetuximab plus chemotherapy group.”
§ Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer > 4. The Epidermal Growth Factor Receptor Pathway > 4.1. Cetuximab
What the sources say
- Supportedcites [20] Bridgewater, 2020, Systemic Chemotherapy with or without Cetuximab in Patients with Resectable Colorectal Liver Metastasis (New EPOC): Long-Term Results of a Multicentre, Randomised, Controlled, Phase 3 Trial, Lancet Oncol. source
The Results section of the New EPOC paper reports median overall survival of 81·0 months with chemotherapy alone and 55·4 months with chemotherapy plus cetuximab. The paper identifies the patients as having resectable colorectal liver metastases. (LLM, conf=0.95)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Pre-clinical studies and early trials have demonstrated improved responses to combined MEK and BRAF inhibition [37,38].”
§ Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer > 4. The Epidermal Growth Factor Receptor Pathway > 4.5. BRAF and MEK Inhibition
What the sources say
- Partly supportedcites [37] Corcoran, 2010, BRAF Gene Amplification Can Promote Acquired Resistance to MEK Inhibitors in Cancer Cells Harboring the BRAF V600E Mutation, Sci. Signal sourceExperimental — accuracy not yet measured
The Results section reports that combined MEK and BRAF inhibition was more potent than either treatment alone in BRAF-mutant cancer cells. The Introduction describes favorable responses in early clinical trials of the inhibitors individually, not trials of the combination. This source therefore supports the preclinical part of the claim but not the claim about improved responses to combined treatment in early trials; page numbers were not provided. (LLM, conf=0.88)
- Partly supportedcites [38] Corcoran, 2018, Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAFV600E-Mutant Colorectal Cancer, Cancer Discov. sourceExperimental — accuracy not yet measured
The Introduction (page not provided) reports a modestly improved response rate of 12% in an early trial of combined BRAF and MEK inhibition. It says preclinical models showed improved pathway suppression, but does not say they showed improved responses. (LLM, conf=0.82)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“A post hoc analysis of the RAISE trial demonstrated that the greatest benefit of ramucirumab therapy was in patients with CEA ≤ 10 versus CEA > 10 [56].”
§ Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer > 5. The Vascular Endothelial Growth Factor Pathway > 5.3. Ramucirumab
What the sources say
- Supportedcites [56] Yoshino, 2017, Baseline Carcinoembryonic Antigen as a Predictive Factor of Ramucirumab Efficacy in RAISE, a Second-Line Metastatic Colorectal Carcinoma Phase III Trial, Eur. J. Cancer source
The Results report a larger overall-survival benefit with ramucirumab in the CEA ≤10 ng/ml subgroup than in the >10 ng/ml subgroup: 3.6 versus 0.8 months of median survival improvement. The Discussion likewise says the benefit was stronger at lower CEA values. The authors describe these as exploratory analyses requiring prospective confirmation. (LLM, conf=0.92)
boostedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“the CONSIGN study was a Phase IIIB study that evaluated the safety profile of regorafenib and demonstrated a reasonable toxicity profile for most patients [60].”
§ Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer > 5. The Vascular Endothelial Growth Factor Pathway > 5.4. Regorafenib
What the sources say
- Supportedcites [60] Martinelli, 2019, Regorafenib for Patients with Metastatic Colorectal Cancer Who Progressed After Standard Therapy: Results of the Large, Single-Arm, Open-Label Phase IIIb CONSIGN Study, Oncologist source
The INTRODUCTION states CONSIGN (NCT01538680) 'was designed to characterize regorafenib safety in a larger patient population' in treatment-refractory mCRC, and the title/abstract frame it as the phase IIIb, single-arm, open-label study — matching the citing sentence's design and purpose. The DISCUSSION supplies the substance of 'reasonable toxicity profile for most patients': regorafenib-related TEAEs led to dose modifications in 60% but discontinuation in only 9%, 'suggesting that regorafenib-related TEAEs were managed with dose modifications, allowing patients to stay on therapy,' and the safety profile was 'consistent with results of the phase III trials.' The CONCLUSION echoes this while adding that high dose-reduction/interruption rates underscore the need for patient selection and AE management — a nuance, not a contradiction, of the paraphrase. (LLM, conf=0.80)
boosted- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“and the FDA has approved their use for these patients.”
§ Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer > 9. Tyrosine Receptor Kinase Fusions > 9.3. Summary
What the sources say
- Supportedcites [84] Doebele, 2020, Entrectinib in Patients with Advanced or Metastatic NTRK Fusion-Positive Solid Tumours: Integrated Analysis of Three Phase 1-2 Trials, Lancet Oncol. source
The Introduction states that the FDA granted accelerated approval to larotrectinib for adults and children with solid tumours harbouring an NTRK fusion. The Discussion states that the FDA granted accelerated approval to entrectinib for the same patient group in August 2019. (LLM, conf=0.94)
- Supportedcites [85] Hong, 2020, Larotrectinib in Patients with TRK Fusion-Positive Solid Tumours: A Pooled Analysis of Three Phase 1/2 Clinical Trials, Lancet Oncol. source
The Introduction states that the FDA approved larotrectinib for adults and children with advanced solid tumours harbouring an NTRK fusion, and similarly approved entrectinib for NTRK fusion-positive disease. This supports the cited statement about both drugs, subject to the paper’s stated advanced-tumour qualification for larotrectinib. (LLM, conf=0.93)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
59 more claims · 6 with their cited sources checked
Create a free account to see all 109 claims and to verify the 81 references still open.
- It may state two separate claims as one. 31
- Probably not a substantial claim. 11
- The quote only partly states this claim. 6
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer > 4. The Epidermal Growth Factor Receptor Pathway > 4.7. Summary
“For patients with KRAS C12C mutations, guidelines recommend the use of sotorasib or adagrasib.”
§ Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer > 4. The Epidermal Growth Factor Receptor Pathway > 4.6. RAS Inhibition
“Two therapies targeting KRAS G12C mutation are currently under investigation. Sotorasib irreversibly binds the KRAS G12C protein.”
Citations
Cites
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968 · cited 1×
“Another trial evaluated the use of bevacizumab as adjuvant therapy after surgery [51].”
BackgroundMutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674 · cited 1×
“Among patients with colorectal cancer, there is an approximately 10% incidence of BRAF mutation [36].”
BackgroundCunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033025 · Cited by 5,035 · cited 2×
“Cetuximab was fi rst approved by the FDA in 2004 after a multicenter, randomized trial in Europe demonstrated promising results among patients with poor response to irinotecan-based regimens [15].”
BackgroundMethodCetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Van Cutsem, E., Köhne, C.-H., Hitre, E., Zaluski, J., Chang Chien, C.-R., Makhson, A., D'Haens, G., Pintér, T., Lim, R., Bodoky, G., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805019 · Cited by 3,877 · cited 1×
“The CRYSTAL trial was a multicenter, phase 3 trial evaluating FOLFIRI plus cetuximab versus FOLFIRI alone for patients with unresectable colorectal cancer [16].”
MethodColorectal cancer statistics, 2023
Siegel, R. L., Wagle, N. S., Cercek, A., Smith, R. A., & Jemal, A. (2023) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21772 · Cited by 3,733 · cited 2×
“Colorectal cancer (CRC) is the third most commonly diagnosed cancer in men and women in the United States and the third leading cause of cancer-related death [1].”
BackgroundMethodWild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
Amado, R. G., Wolf, M., Peeters, M., Van Cutsem, E., Siena, S., Freeman, D. J., Juan, T., Sikorski, R., Suggs, S., Radinsky, R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.7116 · Cited by 3,207 · cited 1×
“Patients must have KRAS wt tumors for panitumumab to be effective [22,23].”
BackgroundPembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer
André, T., Shiu, K.-K., Kim, T. W., Jensen, B. V., Jensen, L. H., Punt, C., Smith, D., Garcia-Carbonero, R., Benavides, M., Gibbs, P., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2017699 · Cited by 3,099 · cited 1×
“The Check-Mate 142 trial was a multinational, multicenter, phase 2 trial that evaluated nivolumab in patients with MSI high tumors refractory to chemotherapy.”
MethodSaltz, L. B., Clarke, S., Díaz-Rubio, E., Scheithauer, W., Figer, A., Wong, R., Koski, S., Lichinitser, M., Yang, T.-S., Rivera, F., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.9930 · Cited by 2,955
Grothey, A., Cutsem, E. V., Sobrero, A., Siena, S., Falcone, A., Ychou, M., Humblet, Y., Bouché, O., Mineur, L., Barone, C., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61900-x · Cited by 2,895 · cited 1×
“This multicenter, randomized trial in China compared fruquitinib to placebo in patients who had progressed on at least two lines of therapy but had not received a VEGF inhibitor.”
MethodOverman, M. J., McDermott, R., Leach, J. L., Lonardi, S., Lenz, H.-J., Morse, M. A., Desai, J., Hill, A., Axelson, M., Moss, R. A., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30422-9 · Cited by 2,836 · cited 1×
“The AtezoTRIBE trial added atezolizumab to FOLFOXIRI plus bevacizumab among patients with microsatellite stable tumors to assess the hypothesis that FOLFOXIRI and bevacizumab may increase the immunogenicity of microsatellite stable tumors [82].”
Method
Cited by
Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer
Haynes, J., & Manogaran, P. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26051988 · Cited by 82
“This type of targeted therapy is only effective in the absence of mutations in , HER2-positive) ) for CRC with BRAF-V600E mutation, used in combination with EGFR inhibitor cetuximab (Figure 2) [14,34].”
InfluentialImmunotherapy for colorectal cancer
Yu, B., Kang, J., Lei, H., Li, Z., Yang, H. C., & Zhang, M. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1433315 · Cited by 43
Rahman, M. A., & Ali, M. M. (2024) · Cancers · doi:10.3390/cancers16172975 · Cited by 28
Chang, W., Peng, J.-Y., Hong, C.-L., Li, P.-C., Chye, S. M., Lu, F., Lin, H.-Y., & Chen, C. (2025) · Antioxidants · doi:10.3390/antiox14070892 · Cited by 26
“…research emphasize the need for personalized therapeutic strategies, particularly for metastatic CRC. Targeted therapies directed at EGFR, VEGF, BRAF, and HER2, as well as immune checkpoint inhibitors (e.g., anti-PD-1), have demonstrated clinical benefit in biomarker-defined patient subgroups [23].”
Unraveling the complexities of colorectal cancer and its promising therapies – An updated review
Saha, S., Ghosh, S., Ghosh, S., Nandi, S., & Nayak, A. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.113325 · Cited by 30
Metadata
- Authors
- Underwood, P. W., Ruff, S. M., & Pawlik, T. M.
- Affiliations
- The Ohio State University Wexner Medical Center (US)
- Corresponding author
- Pawlik, Timothy M.
- Venue
- Cells
- Publisher
- MDPI AG
- Published
- 2024-01-28
- Volume
- 13
- Issue
- 3
- Pages
- 245
- ISSN
- 2073-4409 (ISSN-L)
- PMC
- PMC10854977
- OpenAlex
- W4391314220
- Cited by
- 130
- References
- 89
- Citations by year
- 2026: 56 · 2025: 56 · 2024: 18
- FWCI
- 6.97
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Cells (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
- Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
- Keywords
- metastatic colorectal cancer, targeted therapy, immunotherapy, EGFR, vascular endothelial growth factor, DNA mismatch repair, molecular subtyping, tumor heterogeneity, genetic mutations, carcinogenesis, chemotherapy limitations
- MeSH terms
- Colonic Neoplasms, Humans, Immunotherapy, Rectal Neoplasms, Colorectal Neoplasms, Vascular Endothelial Growth Factor A
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-06, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-06 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer. https://app.cochat.ai/papers/10.3390/cells13030245
- The paper
- Underwood, P. W., Ruff, S. M., & Pawlik, T. M. (2024). Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer. Cells. https://doi.org/10.3390/cells13030245
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.